Background Local drug delivery has substantial potential to prevent infections compared with systemic delivery. Although calcium sulfate (CaSO 4 ) has been studied for local drug delivery and two types are commercially available, it is unknown whether they differentially release antibiotics. Questions/purposes We determined the differences between two sources of CaSO 4 and the K 2 SO 4 catalyst's presence on the degradation, daptomycin elution, and activity against Staphylococcus aureus. Methods We formed pellets from synthetic and naturally sourced (from gypsum) CaSO 4 and loaded with 5% daptomycin and 3% or 0% K 2 SO 4 . We used in vitro experiments to determine the daptomycin concentration and degradation profiles over 10 days. Turbidity assays were used to evaluate the activity of the daptomycin eluates against S. aureus.
Introduction
Wound infection and osteomyelitis can be challenging to treat, especially with complex musculoskeletal trauma in civilian and military populations, and can result in multiple surgeries and increased costs [7, 20] . Local drug delivery is emerging as a useful route for treating acute and chronic wound infections. Because drugs are delivered to the entire body in systemic drug delivery, toxicity issues can often arise as well as antibiotic resistance [9] . Organisms that are typically antibiotic-resistant in systemic delivery can be more susceptible to the higher levels of antibiotics provided through local delivery [9] . Additionally, the drug can take a longer time to reach the wound when delivered systemically and some avascular areas of the body are unreachable [9] . In local drug delivery, the wound area is targeted and the drug does not substantially affect other parts of the body; however, local drug delivery systems do not completely eliminate toxicity issues and antibiotic resistance. The ideal local drug delivery system would be implanted, deliver antibiotics at appropriate levels and lengths of time based on application, and then degrade so there would be no need for a second surgical procedure for removal [9] .
Another difficult challenge with complex musculoskeletal trauma is resistant bacteria. Wound infection can be complicated by wound contamination with antibioticresistant bacteria, which can increase treatment difficulty. Methicillin-resistant Staphylococcus aureus (MRSA) is a serious concern in modern medicine and serves as a problem in wound treatment. Antibiotic-resistant bacteria have created a need for newer antibiotics as an adjunct for past antibiotic selections such as vancomycin. Daptomycin is a semisynthetic antibiotic with activity against Grampositive bacteria and has demonstrated activity against MRSA [6, 15] . Daptomycin has been previously researched combined with a calcium sulfate (CaSO 4 ) carrier, and daptomycin reportedly elutes similarly to tobramycin in vitro [22, 27] . However, like with many antibiotics used for infected wound treatment, bacterial resistance to daptomycin has been recently reported [26] .
CaSO 4 has been previously used as a bone void filler and in bone defects is absorbed by the surrounding tissue, possibly accelerating bone healing [21] . CaSO 4 is a biocompatible, biodegradable material with osteoconductive properties that exhibits a bolus, or burst, release followed by an extended drug release from several hours to weeks depending on the formulation [11, 23] . CaSO 4 has been used to deliver vancomycin, gentamycin, tobramycin, lincomycin, cefazolin, teicoplanin, and fucidin [4, 10, 16] . Another, and the most common, material used for local drug delivery is polymethylmethacrylate (PMMA) [5] . Although PMMA implants are not biodegradable, their removal may be necessary at times for planned staged reconstruction or late bead failure [18] . Because CaSO 4 degrades over time, the need for surgical removal is eliminated. Clinical studies and animal models suggest using antibiotic-loaded calcium sulfate pellets minimizes infection [1, 17, 25] . Although there are numerous potential applications in which calcium sulfate is beneficial as a drug delivery material, the mechanical properties of calcium sulfate do make it insufficient for load-bearing applications [8] . Recently, two sources of CaSO 4 that are commercially available have been studied for their use in local antibiotic delivery. To make pellets with daptomycin from one type of CaSO 4 (hemihydrate synthesized from naturally occurring USP grade gypsum), a catalyst, K 2 SO 4 , is required [22] . It has been proposed the K 2 SO 4 catalyst would not be necessary to form pellets from a synthetic CaSO 4.
A comparison of antibiotic elution, pellet degradation, and the need for a catalyst of these two CaSO 4 sources has not been investigated.
We asked the following questions: (1a) is the pellet degradation and (1b) daptomycin elution profile different for two different forms of CaSO 4 , naturally sourced from gypsum and synthetic; (2) does the presence of a catalyst, potassium sulfate (K 2 SO 4 ), affect the degradation and the daptomycin elution profile of the CaSO 4 pellets manufactured from two different sources; and (3) is the daptomycin released from both sources of CaSO 4 pellets active against bacteria associated with osteomyelitis, specifically S. aureus?
Materials and Methods
To determine whether the pellet degradation, daptomycin elution profile, and activity against S. aureus were affected by the type of CaSO 4 or the presence of a catalyst, we prepared the CaSO 4 pellets in three groups, synthetic CaSO 4 and 3% K 2 SO 4 , synthetic CaSO 4 and 0% K 2 SO 4 , and naturally sourced CaSO 4 with 3% K 2 SO 4 ( Fig. 1 ). Four of each type of pellet was placed in each vial and there were four total replications, or vials, for each group in each test. Each pellet group was tested in an elution study, 4 , with and without 5 wt%, 0.25 g, of daptomycin (Cubist Pharmaceuticals Inc, Lexington, MA; Lot MCB2007). The 5 wt% was previously determined using prior research on naturally sourced CaSO 4 pellets [22, 27] . Throughout our study, we used aseptic techniques in the fabrication of the pellets. The synthetic CaSO 4 pellets were made with and without 2.5 mL of sterilized 3% K 2 SO 4 solution, whereas the naturally sourced CaSO 4 pellets were only made with 2.5 mL of 3% K 2 SO 4 solution. Previous research has determined that a concentration of 3% K 2 SO 4 is necessary for the naturally sourced CaSO 4 pellets because the pellets will not retain their shape without the catalyst [27] . The 3% K 2 SO 4 solution was substituted with 1.7 mL of sterile phosphate-buffered saline for the synthetic CaSO 4 pellets with 0% K 2 SO 4 . We carried out all experiments in four replications (n = 4). Pellets were cast using 3-mm OSTEOSET1 Resorbable Mini-Bead Kits (Wright Medical Technology; Catalog 8400-0511; Lot LB04-0028-27) and following the mixing method used by Wright Medical Technology described in previous research [22, 27] .
We performed the elution statically with four sets of each pellet variation distributed into four steam autoclaved 20-mL glass scintillation vials. The elution was conducted without stirring to maintain the structure of the pellets. We loaded 4 mL of phosphate-buffered saline (PBS) into each vial and placed them in an oven at 37°C. The eluates were mixed and 1-mL samples were taken at Days 1, 2, 4, 6, 8, and 10. The elution studies were stopped at 10 days because the antibiotic levels were below the highperformance liquid chromatography detection limit. After each day's eluate sample was collected, we replaced the remaining liquid with a fresh 4 mL PBS and the vials were returned to the 37°C oven. Eluate samples were immediately frozen in a Fisher Scientific Isotemp freezer at À20°C.
To measure the initial daptomycin concentration loaded in the pellets, samples were made of each pellet variation were constructed and crushed before placing them into a PBS solution. The drug content of the pellets was measured before the elution because previous CaSO 4 and daptomycin pellets had some daptomycin loss from initial loading. The percent daptomycin content loaded into the pellets was compared with the percent daptomycin released from the elution.
To determine the eluate's antibiotic concentration, we performed high-pressure liquid chromatography (HPLC) testing according to previously used methods [22] . The Varian (Palo Alto, CA) HPLC system was comprised of a ProStar 240 Solvent Delivery, ProStar 410 Autosampler, and ProStar 325 UV-Vis Detector modules. We performed module control and data processing using Varian's Galaxie Chromatography Data System (Version 1.8.508.1). The mobile phase consisted of a HPLC-grade acetonitrile and water (62:38, v/v) solution including 4 mM ammonium dihydrogen phosphate brought to a pH of 3.25 using glacial acetic acid. Separation was accomplished using a Varian Microsorb-MV C8 column, 150-mm length and 4.6-mm inner diameter, with a flow rate of 1 mL/min. Daptomycin was detected at 232 nm with a retention time of 13.8 minutes. We performed the method in a temperature range of 23.3 ± 1.1°C.
We determined the CaSO 4 pellets' degradation by a common weight-based experiment [2, 22, 24] . Initially, the weights of clean 20-mL glass scintillation vials were established and then the weight of each vial with four pellets of an individual variation was measured. We loaded 4 mL of PBS into each vial and stored them at 37°C. At 1-, 2-, 4-, 6-, 8-, and 10-day time points, the PBS was removed and the pellets were allowed to dry at 70°C until a constant vial and pellet weight was obtained. After each time point's sample was collected, we placed 4 mL PBS into the vials and they were returned to 37°C storage. The degradation was determined by the percent of pellets remaining at each time point calculated using the following relationship: Percent remaining % ð Þ ¼ À vial and pellets at Â hours weight À vial weight Á mg ð Þ= vial and initial pellets weight À vial weight ð Þ mg ð ÞÂ100
We determined antibiotic activity against S. aureus (Cowan I strain obtained from Dr David Hasty, University of Tennessee Health Science Center) by using antibiotic elution samples in a turbidity assay. In this experiment, solution clarity after sufficient bacterial incubation with antibiotic eluates indicated bacterial inhibition resulting from antibiotic activity. As instructed by the protocol provided by the manufacturer, we supplemented BBL TM Mueller Hinton II Broth (Becton, Dickinson and Co, Sparks, MD; Lot 0071612) with 25 lg/mL Ca 2+ to achieve a total Ca 2+ concentration of 50 lg/mL. Two hundred microliters of daptomycin eluates were added to the inoculum containing 1.75 mL Mueller Hinton II Broth + Ca 2+ and 50 lL S. aureus in 5-mL polystyrene test tubes. The experimental setup created a 1:10 dilution of all eluates.
Experimental groups, blanks containing neither S. aureus nor eluate samples, and positive controls containing S. aureus without antibiotic eluates were mixed and incubated at 37°C. After approximately 20 hours of incubation at 37°C, we vortexed the tubes and the absorbance at 530 nm was recorded.
All data are presented as mean ± SD and met the assumptions of a parametric test. We determined differences in percent degradation and daptomycin concentration between the pellets made from two different types of CaSO 4 and the pellets made with and without K 2 SO 4 using repeated measures analysis of variance and Tukey's post hoc analysis using 2007 Microsoft Office Excel (Microsoft Inc, Redmond, WA) and 2004 SigmaStat (San Jose, CA). Differences in degradation were also analyzed with Kaplan-Meier survival analysis with log rank, in which 10% of the original pellet remaining was classified as failure of the pellets. When only 10% of the original pellet remains, the antibiotic concentration in the pellets is typically too low and the pellets are too small to accurately measure.
Results
The degradation studies indicated differences between the sourced and synthetic CaSO 4 pellets with 3% K 2 SO 4 without daptomycin (Fig. 2) at Days 2 (p = 0.002), 4, 6, and 8 (p \ 0.001). However, Kaplan-Meier analysis with log rank revealed no overall differences among all three CaSO 4 groups without daptomycin (p = 0.368). When 5 wt% daptomycin was incorporated into the pellets (Fig. 3) , differences were seen between the sourced CaSO 4 pellets and the synthetic CaSO 4 with 0% K 2 SO 4 at Days 1 through 10 (p \ 0.001). Using Kaplan-Meier analysis with log rank, overall differences were seen between the sourced and synthetic CaSO 4 pellets with 0% K 2 SO 4 (p \ 0.001) and between the synthetic CaSO 4 pellets with 3% and 0% K 2 SO 4 (p \ 0.001). However, no differences were seen between the degradation of the sourced and the synthetic CaSO 4 pellets with 3% K 2 SO 4 (p [ 0.05) from the analysis of variance or Kaplan-Meier survival analysis.
We observed differences in the elution profile of the sourced CaSO 4 pellets and the synthetic CaSO 4 pellets with 3% K 2 SO 4 at Day 1 (p \ 0.001) and Day 2 (p = 0.002) (Fig. 4) . The sourced CaSO 4 pellets released the highest amount of daptomycin on Day 1 and correspondingly had the highest amount of cumulative daptomycin eluted ( Fig. 5 ), but the synthetic CaSO 4 pellets with 3% K 2 SO 4 released the largest amount of antibiotic on Day 2. For evaluation of mass balance in these studies, the average percent daptomycin loaded and released from the three types of pellets was measured. The average percent of daptomycin for the sourced CaSO 4 pellets was highest at loading, at 85.1%, but the percent daptomycin released was highest in the synthetic CaSO 4 pellets with 3% K 2 SO 4 at 48.8% ( Table 1 ). The average percent daptomycin was 
% of Original Pellet Remaining

Time (days)
Sourced CaSO4 pellets, 3% K2SO4, 0% daptomycin Synthetic CaSO4 pellets, 3% K2SO4, 0% daptomycin Synthetic CaSO4 pellets, 0% K2SO4, 0% daptomycin p = 0.002 p = 0.010 p = 0.002 * p = 0.033 * * p = 0.009 * * p = 0.001 Fig. 2 The graph shows the degradation results of the naturally sourced and synthetic CaSO 4 pellets with 0% daptomycin present. There were differences in average degradation of naturally sourced and synthetic CaSO 4 pellets with 3% K 2 SO 4 and naturally sourced and synthetic CaSO 4 pellets with 0% K 2 SO 4 at Days 2, 4, 6, and 8.
Differences were observed between the synthetic CaSO 4 pellets with 3% and 0% K 2 SO 4 at Days 4, 6, and 8. Degradation is reported in wt% of original pellet remaining ± SD with n = 4 (* p \ 0.001). 
% of Original Pellet Remaining
Time (days)
Sourced CaSO4 pellets, 3% K2SO4, 5% daptomycin Synthesized CaSO4 pellets, 3% K2SO4, 5% daptomycin Synthesized CaSO4 pellets, 0% K2SO4, 5% daptomycin * * * * * Fig. 3 The graph shows the degradation results of the naturally sourced and synthetic CaSO 4 pellets with 5% daptomycin present. We observed differences in average degradation of naturally sourced and synthetic CaSO 4 pellets with 0% K 2 SO 4 and synthetic CaSO 4 pellets with 3% and 0% K 2 SO 4 at Days 1-10. Degradation is given in wt% of original pellet remaining ± SD with n = 4 (* p \ 0.001).
lowest, both loaded and released, in the synthetic CaSO 4 pellets with 0% K 2 SO 4 .
The presence or absence of K 2 SO 4 created differences in the degradation and the elution in the synthetic CaSO 4 pellets. The synthetic CaSO 4 pellets with 0% K 2 SO 4 and 5 wt% daptomycin degraded much more quickly than both types of pellets with 3% K 2 SO 4 , and as previously mentioned, differences were seen in degradation between the synthetic CaSO 4 pellets with 0% K 2 SO 4 and the other pellets using analysis of variance and Kaplan-Meier analysis. Differences were seen in the elution (Fig. 4) between the synthetic CaSO 4 pellets with 0% K 2 SO 4 and 3% K 2 SO 4 at Day 2 (p \ 0.001) and the naturally sourced CaSO 4 pellets with 3% K 2 SO 4 at Day 1 (p \ 0.001) and Day 2 (p = 0.002).
The eluates of the sourced CaSO 4 pellets with 3% K 2 SO 4 and 5 wt% daptomycin demonstrated sufficient activity against S. aureus with no bacterial growth at Days 1, 4, and 6 ( Table 2) . Eluates from synthesized CaSO 4 pellets with 0% K 2 SO 4 were only active against S. aureus at Days 1 and 2; however, the eluates from the synthesized CaSO 4 pellets with 3% K 2 SO 4 were active against S. aureus at all time points except at 10 days.
Discussion
The treatment of osteomyelitis is becoming complicated by the increased emergence of antibiotic-resistant bacteria and increases the need for local drug delivery over systemic delivery. The purpose of our study was to evaluate parameters of a local CaSO 4 drug delivery system, including 
Elution Time (days) Daptomycin concentration released Daptomycin mass released per pellet (µg)
Sourced CaSO4 pellets with 3% K2SO4 Synthetic CaSO4 pellets with 3% K2SO4 Synthetic CaSO4 pellets with 0% K2SO4 * * p = 0.002 p = 0.020 * per pellet (µg/ml) Fig. 4 The graph shows the elution results from the naturally sourced and synthetic CaSO 4 pellets with 5% daptomycin loaded with mass and concentration of daptomycin released on the primary and secondary y axes, respectively. We found differences in the average mass and concentration of daptomycin released in the eluates between the naturally sourced and synthetic CaSO 4 pellets with 3% and 0% K 2 SO 4 at Days 1 and 2. Differences are shown in average mass and concentration of daptomycin released in the eluates between the synthetic CaSO 4 pellets with 3% and 0% K 2 SO 4 at Day 2. Mass and concentration are given in micrograms and micrograms per milliliter, respectively, of daptomycin released per pellet ± SD with n = 4 (* p \ 0.001). Cumulative Daptomycin mass released
Elution Time (days)
Sourced CaSO4 pellets, 3% K2SO4, 5% daptomycin Synthesized CaSO4 pellets, 3% K2SO4, 5% daptomycin Synthesized CaSO4 pellets, 0% K2SO4, 5% daptomycin per pellet (µg) Fig. 5 The graph shows the elution results in the cumulative release form from the naturally sourced and synthetic CaSO 4 pellets, with and without 3% K 2 SO 4 , with 5% daptomycin loaded. Mass is given in micrograms of daptomycin released per pellet ± SD with n = 4. Values are mean (n = 4). (1a) to determine if the pellet degradation and (1b) daptomycin elution profile is different for two different commercially available forms of CaSO 4 ;
(2) to examine if the presence of a catalyst, K 2 SO 4 , affects the degradation and antibiotic elution profile of the CaSO 4 pellets; and (3) to verify the daptomycin released from both types of CaSO 4 pellets is active against S. aureus, a bacterium commonly associated with osteomyelitis. Our study is limited by several factors. First, a common limitation of most in vitro research is the difficulty of translating in vitro studies to in vivo studies [18] . Release characteristics in an in vivo environment, especially associated with a wound, are different than antibiotic release characteristics in vitro, in which a set volume of eluate and PBS is exchanged at certain intervals [18] . This study is not meant to serve as a surgical wound model itself but as a supplement to in vivo studies. Additionally, although we are testing four pellets at one time, elution, degradation, and activity properties of these pellets may be completely different in vivo in larger pellet quantities. Second, we tested activity of the antibiotic to planktonic S. aureus and did not test inhibitory activity to bacteria within biofilms, which can be more resistant to antibiotic therapy and typically require additional antibiotic levels required for inhibition of planktonic bacteria [3] . Third, we used only one antibiotic. Increasing the number of evaluated antibiotics could predict if the CaSO 4 type or presence of K 2 SO 4 impacts drug elution and pellet degradation in different ways. Fourth, both elution and degradation are dependent on numerous factors, including physical and chemical properties of materials, elution volumes with and without fluid exchange, and antibiotic interactions and thus we cannot predict elution and degradation performance across all potential applications. Both elution and degradation studies only provide details about the release and degradation characteristics of the local delivery vehicle itself and do not account for affects from a local wound and the interactions among the delivery system, fluid, and drug.
Our preliminary data indicate differences in degradation and elution between both forms of CaSO 4 pellets, naturally sourced and synthetic, that could affect the clinical selection of a local delivery system. Like with previously researched sourced CaSO 4 pellets, all pellets exhibited a bolus release of antibiotics on Day 1 [21, 26] . However, the total percent release of daptomycin from the naturally sourced CaSO 4 pellets was higher and the concentration of daptomycin released on Day 1 was lower than previously reported (Table 3) [22, 27] . The initial daptomycin released from the naturally sourced and synthetic calcium sulfate pellets is closer to initial antibiotics eluted from PMMA beads (Table 3) [13, 14, 19 ]. An explanation for the higher total release of the antibiotic could be the result of faster elution to measurement activities in comparison to previous studies. Extended elution and storage could impact stability of daptomycin in solution. The lower initial daptomycin concentration could be explained by the larger size of the previously researched CaSO 4 pellets [21, 26] . Although the synthetic CaSO 4 pellets also exhibited a bolus release, more daptomycin was eluted on Day 2 compared with the naturally sourced CaSO 4 pellets, which could demonstrate slower antibiotic release. The difference in daptomycin release could be partially explained by the degradation differences between the types of pellets. The synthetic CaSO 4 pellets with 3% K 2 SO 4 and 5% daptomycin demonstrated the slowest degradation as compared with the other two types of pellets. Although the naturally sourced CaSO 4 pellets had a faster degradation than the synthetic CaSO 4 pellets with 3% K 2 SO 4 , the degradation of the naturally sourced CaSO 4 pellets in our study was slower than previously reported [22] . However, the results could have been different because distilled water was used for the degradation solution instead of PBS in the previous research [22] . The presence of daptomycin increased the degradation rate in all three pellet types studied but had the greatest effect on the degradation of the synthetic CaSO 4 pellets with 0% K 2 SO 4 . An explanation for this difference in degradation that has been previously reported could be that when the K 2 SO 4 is absent, the daptomycin prevents the setting reaction of the CaSO 4 , which impacts the stability of pellets [21] .
Although it has been previously determined that K 2 SO 4 is necessary to form pellets of naturally sourced CaSO 4 [22] , we were able to form pellets out of synthetic CaSO 4 without the K 2 SO 4 catalyst. By not incorporating K 2 SO 4 into the pellets, the synthetic CaSO 4 pellets degraded much more rapidly and released less daptomycin than the other pellets with the catalyst present. The daptomycin released from the synthetic CaSO 4 pellets with 0% K 2 SO 4 is substantially less than the amount released from the same type of CaSO 4 with 0% K 2 SO 4 that was previously reported (Table 3 ) [12] . However, the local delivery pellets used in these previous research studies were much larger than the pellets in this current research, 160 by 100 mm compared with 3-mm pellets, and Mueller Hinton broth was used as the elution vehicle instead of PBS [12] .
Our preliminary data suggest the eluted daptomycin from both naturally sourced and synthetic CaSO 4 pellets, with and without K 2 SO 4 , is active against S. aureus, inhibiting bacterial growth for varying lengths of time. Although the synthetic CaSO 4 pellets with 3% K 2 SO 4 demonstrated the highest activity against S. aureus, the synthetic pellets with 0% K 2 SO 4 provided inhibition of S. aureus on Days 1 and 2 only, which can be explained by the low amount of daptomycin eluted from the pellets compared with the pellets with K 2 SO 4. The inhibitory activity of the synthetic pellets with 0% K 2 SO 4 is much lower than previously reported daptomycin inhibition of S. aureus from CaSO 4 and PMMA; however, the bacterial inhibition of the synthetic CaSO 4 pellets with 3% K 2 SO 4 is much higher than the same reported data [12, 26] . The positive growth measured on Day 2 for the naturally sourced CaSO 4 pellets may have been caused by an unknown contaminant because there were similar amounts of daptomycin present in the pellets on Days 4 and 6. Additionally, similar naturally sourced CaSO 4 pellets were previously reported to inhibit S. aureus for 10 days without any contamination and inhibited S. aureus for 28 days with two cases of contamination [27] .
This preliminary research provides researchers and clinicians with additional information on the two commercially available forms of CaSO 4 for a local delivery system for infection prevention or treatment. Our data also show that although K 2 SO 4 is not necessary for forming pellets from synthetic CaSO 4 , it may be helpful for decreased degradation, an increased daptomycin elution profile, and potentially extended activity against susceptible organisms. Further investigations, including preclinical in vivo studies and biofilm-associated investigations, are needed to determine functional differences and applications of these local drug delivery systems.
